Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Liver International · 2025-05 · 45 (5)
DOI: 10.1111/liv.70060 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Liver International, online erschienen am 21.04.2025. Verfasst von Byungyoon Yun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Research Foundation of Korea, the National Research Foundation of Korea, the Korea Government (MSIT).
Abstract (Originalsprache)
Background
The prevalence of diabetes is increasing among chronic hepatitis B (CHB) patients. However, the relative efficacy of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP4i), compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), among such at‐risk populations remains unclear in terms of reducing liver‐related events (LRE).
Methods
Using a nationwide database (2019–2022), we identified CHB patients with diabetes (age ≥ 40) and established two new‐user cohorts: SGLT2i vs. GLP‐1RA and DPP4i vs. GLP‐1RA. LREs included hepatocellular carcinoma, cirrhosis, liver transplantation and liver‐related mortality. For appropriate balancing, propensity score matching (PSM) was performed for each cohort. Multivariate Cox regression models were used to estimate LRE risk with adjusted hazard ratios (aHR) and 95% confidence intervals (CI).
Results
Propensity score matching provided two separate cohorts: (1) SGLT2i ( n = 2297) vs. GLP‐1RA ( n = 461) and (2) DPP4i ( n = 803) vs. GLP‐1RA ( n = 165) users. The LREs risk was similar across each comparison, with aHRs of 0.82 (95% CI 0.49–1.37) for GLP‐1RA (vs. SGLT2i) and 0.93 (95% CI 0.41–2.07) for GLP‐1RA (vs. DPP4i), indicating no significant differences. Subgroup analyses showed a trend favouring GLP‐1RA over SGLT2i in females, obese individuals, antiviral therapy (AVT) users, those with diabetes complications, longer diabetes duration and physically active individuals. Compared with DPP4i, the trend was observed in AVT users and those with a shorter diabetes duration, though none were statistically significant.
Conclusion
Overall LRE risk was comparable between SGLT2i or DPP4i vs. GLP‐1RA users. Further prospective studies are required to identify who can benefit from specific medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.
- The Institute for Occupational Health, Yonsei University College of Medicine, Seoul, Korea.
- The Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul, Korea.
- Department of Public Health, Graduate School, Yonsei University, Seoul, Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Beom Kyung Kim
Förderung
- National Research Foundation of Korea
- the National Research Foundation of Korea
- the Korea Government (MSIT)
- Ministry of Science and ICT, South Korea
Zitieren
APA
Yun, B., Oh, J., Park, H., Lee, J., Kim, B. K., & Yoon, J. H. (2025). Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients. Liver International, 45(5). https://doi.org/10.1111/liv.70060
Vancouver
Yun B, Oh J, Park H, Lee J, Kim BK, Yoon JH. Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients. Liver International. 2025;45(5). doi:10.1111/liv.70060
BibTeX
@article{Yun2025,
author = {Yun, Byungyoon and Oh, Juyeon and Park, Heejoo and Lee, Jian and Kim, Beom Kyung and Yoon, Jin-Ha},
title = {Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients},
journal = {Liver International},
year = {2025},
volume = {45},
number = {5},
doi = {10.1111/liv.70060}
}
EUVIMED